[Federal Register: January 28, 1999 (Volume 64, Number 18)] [Notices] [Page 4454-4455] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr28ja99-92] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, Oncogene [[Page 4455]] Deregulation Tumor Suppressor Gene Loss of Function in CLL. Date: March 3, 1999. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: 6130 Executive Boulevard, Rockville, MD 20852. Contact Person: Kevin Ryder, Scientific Review Administrator, Grants Review Branch, National Cancer Institute, EPN Room 635, 6130 Executive Blvd. MSC 7408, Bethesda, MD 20892-7408, 301-402-2785. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 22, 1999. LaVerne Y. Stringfield, Committee Management Officer, NIH. [FR Doc. 99-1963 Filed 1-27-99; 8:45 am] BILLING CODE 4140-01-M